key: cord-0269958-uc59mfcz
authors: Hong, E.; Almond, L. M.; Chung, P. S.; Rao, A. P.; Paul, B. M.
title: PBPK-led guidance for the treatment of cystic fibrosis patients taking elexacaftor-tezacaftor-ivacaftor with the newly approved fixed dose combination nirmatrelvir-ritonavir (PAXLOVID) for the treatment of COVID-19
date: 2022-01-21
journal: nan
DOI: 10.1101/2022.01.20.22269253
sha: 9414c36f920d80068c4d0c5a5a4e8d11b7def975
doc_id: 269958
cord_uid: uc59mfcz

Background: Cystic fibrosis transmembrane conductance regulator (CFTR) modulating therapies including elexacaftor, tezacaftor, and ivacaftor (ETI) are primarily eliminated through cytochrome P450 (CYP) 3A-mediated metabolism. This creates a therapeutic challenge to the treatment of COVID-19 with nirmatrelvir-ritonavir in people with cystic fibrosis (pwCF) due to the potential for significant drug-drug interactions (DDI). However, pwCF are more at risk of serious illness following COVID-19 infection and hence it is important to manage the DDI risk and provide treatment options. Methods: CYP3A-mediated DDI of ETI was evaluated using a physiologically based pharmacokinetic (PBPK) modeling approach. Modeling was performed incorporating physiological information and drug dependent parameters of ETI to predict the effect of ritonavir (the CYP3A4 inhibiting component of the combination) on pharmacokinetics of ETI. The ETI models were verified using independent clinical pharmacokinetic and DDI data of ETI with a range of CYP3A modulators. Results: When ritonavir was administered on day 1 through 5, the predicted AUC ratio of ivacaftor (the most sensitive CYP3A substrate) on day 6 was 9.31, indicating that its metabolism was strongly inhibited. Based on the predicted DDI, the dose of ETI should be reduced when co-administered with nirmatrelvir-ritonavir to elexacaftor 200mg-tezacaftor 100mg-ivacaftor 150mg on days 1 and 5, with resumption of full dose ETI on day 9, considering the residual inhibitory effect of ritonavir as a mechanism-based inhibitor. Conclusions: Coadministration of nirmatrelvir-ritonavir requires a significant reduction in the ETI dosing frequency with delayed resumption of full dose due to the mechanism-based inhibition with ritonavir.

The introduction of the Cystic Fibrosis Transmembrane Conductance Regular (CFTR) 40 modulator, a triple combination of elexacaftor, tezacaftor, and ivacaftor (ETI, TRIKAFTA®) has 41 resulted in significant improvements in lung function and nutritional status in people with cystic 42 fibrosis (pwCF) (1) . While ETI is indicated in up to 90% of the CF population(1), all 3 components 43 are eliminated mainly through cytochrome P450 (CYP) 3A-mediated hepatic metabolism(2), and 44 therefore present a therapeutic challenge in pwCF due to the potential for significant drug-drug 45 interactions (DDI). The use of strong CYP3A inducers will increase the metabolism of ETI resulting 46 in reduced exposure and a potential lack of efficacy, while concomitant therapy with agents that 47 inhibit CYP3A will increase ETI levels placing the patient at increased risk of dose-related adverse 48 effects. Therefore, the safe and effective use of CFTR modulators requires appropriate DDI 49 management with concomitant CF medications. 50

One notable therapeutic challenge is in the treatment of COVID-19 (SARS-CoV-2). In 51 pwCF, viral respiratory tract infections can lead to acute pulmonary exacerbations with a negative 52 impact on lung function(3). COVID-19 infection triggers a cytokine storm which can lead to the life-53 threatening respiratory distress syndrome, potentially putting CF population infected with COVID-54 19 be at high risk of serious illness(4). The U.S. Food and Drug Administration (FDA) has recently 55 issued an emergency use authorization (EUA) for the use of the nirmatrelvir-ritonavir for the 56 treatment of mild-to-moderate COVID-19. Nirmatrelvir, is a SARS-CoV-2 main protease inhibitor, 57 and ritonavir, an HIV-1 protease inhibitor and CYP3A4 inhibitor, are co-packaged for oral use. 58

Nirmatrelvir-ritonavir treatment significantly reduces hospital admissions and deaths among people 59 with COVID-19 who are at high risk of severe illness(5). Nirmatrelvir is co-administered with 60 ritonavir, a CYP3A-inhibitor, to boost nirmatrelvir concentrations to achieve therapeutic levels(5). 61

However, due to the potent inhibition effect of ritonavir, it may increase plasma concentrations of 62 drugs that are primarily metabolized by CYP3A. Therefore, co-administration of nirmatrelvir-63 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 21, 2022. ; https://doi.org/10.1101/2022.01.20.22269253 doi: medRxiv preprint ritonavir is contraindicated with drugs highly dependent on CYP3A for clearance and for which 64 elevated concentrations are associated with serious and/or life-threatening reactions. Since all 3 65 components of ETI are eliminated mainly through CYP3A, nirmatrelvir-ritonavir is expected to 66 exhibit a significant drug interaction with ETI. Thus, the use of nirmatrelvir-ritonavir in pwCF would 67 require an adjusted dosing regimen of ETI to prevent increased plasma concentrations and potential 68 adverse drug reactions. However, there is currently no clinical data available regarding the 69 interactions of ETI with nirmatrelvir-ritonavir and no specific dosing guidelines have been 70 established. Therefore, there is an urgent need for the proper guidance regarding the use of 71 nirmatrelvir-ritonavir for pwCF to prevent progression of COVID-19 to severe disease. 72

This study aimed to investigate the magnitude of the drug interactions of ritonavir-ETI, to 73 simulate possible treatment scenarios and provide dosing recommendations to overcome the 74 interaction. The CYP3A inhibition-mediated drug interaction of ETI was evaluated using a 75 physiologically based pharmacokinetic (PBPK) simulation-based approach. PBPK simulation is a 76 tool to predict the pharmacokinetic behavior of drugs in humans by integrating the information from 77 multiple in vitro and clinical studies, exploring the effects of drug (e.g., physicochemical properties) 78 and system (e.g., physiological) information on drug exposure. The predictive performance of PBPK 79 simulations for CYP enzyme-based DDIs has been well established(6, 7), and this strategy is 80 increasingly included during regulatory review by the FDA as an alternative for exploring DDI 81 potential to provide dosing recommendations in product labeling(8). The present study contributes to 82 improved treatment for COVID-19 in pwCF, by providing tools to evaluate and potentially overcome 83 clinically important drug interactions involving highly active CFTR modulator therapy. 84 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

The workflow adopted for PBPK model development, verification, and application are 86 illustrated in Figure 1 . The models were implemented within the Simcyp Simulator (version 19;  87 Certara, Sheffield, UK). provided in Simcyp ® , the distribution of ages and proportion of female were corrected to reflect the 96 demographics of CF population based on patient registry 2020 annual report published by cystic 97 fibrosis foundation(9). Specifically, the frequency of population aged 18-21 years, was adjusted from 98 4.5% in healthy population to 13.1% in CF. Also, the proportion of females was adjusted from 0.32 99 in healthy population to 0.48 in CF. The resulting body mass index (BMI) of the virtual population 100 (mean 25.9 kg/m2) was similar to that observed in CF (21.2 kg/m2 in 2005 to 23.1 kg/m2 in 101 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 21, 2022. ; https://doi.org/10.1101/2022.01.20.22269253 doi: medRxiv preprint 2020(9)) and no further adjustment was needed. This perhaps reflects how BMI in pwCF has been 102 increased over the years with continued improvements in CF care, and is now similar to the mean 103 value of healthy volunteers (23.5 kg/m2)(10). All other system parameters were kept as the default 104 healthy, and this assumption is in line with the PK parameters of ETI not differing between healthy 105 adults and patients with CF(11-13). This population library file was used for all simulations. Ivacaftor is a diprotic acid with an acid dissociation constant (pKa) of 9.4 and 11.6. Ivacaftor has a 118 logP of 5.68, and predominantly binds to albumin with fraction of unbound drug in plasma of 0.001. 119

The blood/plasma partition ratio was 0.55. The absorption parameter Peff,man was predicted by the 120

Simcyp calculator based on its physicochemical properties. The distribution parameters including 121

Vsac and Vss were obtained from published data. The in vitro studies and clinical DDI data suggest 122 that ivacaftor is predominantly eliminated through CYP3A mediated hepatic metabolism(13). 123 Therefore, the excretion was set to enzyme kinetics to quantify its metabolism by CYP3A. The 124 intrinsic clearance by CYP3A4 was back calculated from the oral clearance observed in healthy 125 subjects (19.0 L/h)(11). The fraction of ivacaftor being metabolized by CYP3A (fmCYP3A) was set 126 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 21, 2022. ; https://doi.org/10.1101/2022.01.20.22269253 doi: medRxiv preprint to 98% in order to capture the observed drug interactions of ivacaftor with the strong CYP3A 127 modulators, ketoconazole or rifampin. The Fg was also optimized to 0.50 using observed DDI data. 128

The additional human liver microsomes (HLM) clearance representing non-CYP3A pathways was 129 also estimated using the retrograde calculator and entered into the model to capture the observed 130 pharmacokinetics profiles. 131

The tezacaftor and elexacaftor PBPK models were constructed based on the data from the PBPK 132 review section within the NDA documents and the publication of Tsai et al(12, 13, 17). Briefly, the 133 elexacaftor and tezacaftor models consist of the first-order absorption and a minimal PBPK model. 134

In the NDA document, it was described that the absorption and distribution parameters were 135 obtained from the observed PK profiles following clinical phase 1-3 studies, and the fmCYP3A of 136 elexacaftor and tezacaftor were set to 67% and 73.2% based on human ADME studies. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 21, 2022. ; https://doi.org/10.1101/2022.01.20.22269253 doi: medRxiv preprint

The PK profiles of ETI following multiple administrations of clinically relevant doses (elexacaftor 151 200mg qd, tezacaftor 100mg qd, and ivacaftor 150mg q12h) were first simulated to verify the 152 performance of the PBPK models. We simulated PK of ETI in healthy individuals (48% females) 153 aged between 18-65 years old in line with the clinical study design. ETI was orally administered 154 under fed conditions to mimic the clinical setting, where the fat-containing food is required for 155 optimal absorption of ETI. The simulated data were qualified using the observed PK data in a CF 156 population aged older than 17 years old. The prediction accuracy for the area under the curve (AUC) 157 and maximum plasma concentration (Cmax) values were calculated as a ratio of mean observed values 158 over mean predicted values. Successful model performance was defined by mean ratios of AUC and 159

Cmax within a two-fold range as previously described (20, 21 The assessment of DDI prediction success was based on whether predictions fall within a two-fold 179 range of the observed data. 180 181

Although ritonavir-nirmatrelvir (PAXLOVID) is a fixed dose combination of 2 drugs, nirmatrelvir 183 has not been included in simulations as there is no clinical evidence that it modulates CYP3A4 184 activity, and we have focused on interactions with ritonavir which is a potent CYP3A4 inhibitor. The 185 verified PBPK DDI model was applied to (1) predict the effect of ritonavir on the PK of ETI and (2) 186 determine a potential dose alteration of ETI to overcome the CYP3A inhibition mediated by 187 ritonavir. We first simulated the steady-state PK of standard dose ETI alone and when co-188 administered with 100mg ritonavir twice daily for 5 days based on the instruction for dosage and 189 administration in the FDA-approved fact sheet of nirmatrelvir-ritonavir (5). The extent of the DDI 190 was defined as the geometric mean ratios of AUC or Cmax of ETI with or without concomitant 191 ritonavir. In addition, since ritonavir acts as a mechanism based CYP3A4 inhibitor by covalently 192 binding to the CYP3A4 protein(23), simulations were run until CYP3A4 and the PK of ETI had 193 returned to baseline (10 days after ritonavir discontinuation). We then simulated several adjusted 194 dosing regimens of ETI when co-administered with ritonavir to find the regimen that could provide 195 the closest PK profiles of standard dosing of ETI alone. 196 197 3. Results 198

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in we predicted DDI with ketoconazole by varying the fmCYP3A4 value of ivacaftor from 95% to 204 100% (Figure S1A) , since it has been reported that the fractional metabolism of ivacaftor assigned to 205 CYP3A is greater than 95%(17). An fmCYP3A4 of 98 % predicted the AUC ratio (GMR 6.95) of 206 ivacaftor within the bioequivalence limit (80-125%) of the observed AUC ratio (GMR 8.45). 207

Repeating this analysis for rifampicin, indicated the magnitude of DDI was well captured with 208 fmCYP3A4 between 98 and 100% (simulated GMR 0.11 vs. observed 0.11) ( Figure S2B) . Taken 209 together, the fmCYP3A4 value of 98% was chosen as it describes observed DDIs between ivacaftor 210 and ketoconazole or rifampin within the bioequivalence limit. Further verification of the model was performed by simulating the steady-state PK of ETI when 222 administered with multiple oral doses of elexacaftor 200mg qd, tezacaftor 100mg qd, and ivacaftor 223 150mg q12h. The predicted steady-state AUC and Cmax of ETI were in the range of 0.9 to 1.2 of the 224 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

Although preliminary PK simulations verified the predicted PK ETI, given that the PBPK models of 232 ETI are intended to be applied for the characterization of DDIs involving CYP3A modulation, it is 233 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 21, 2022. ; https://doi.org/10.1101/2022.01.20.22269253 doi: medRxiv preprint essential to verify the victim properties defined in the models (fmCYP3A4 and Fg) by simulating 234 independent clinical DDI studies with a range of perpetrator drugs. The robustness of the model was 235 assessed by comparing the magnitude of simulated DDIs of ETI with that observed from the clinical 236 trials(11-13). The PBPK-DDI models accurately recapitulated the observed DDI magnitude (Table  237 2). 238 preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted January 21, 2022. ; https://doi.org/10.1101/2022.01.20.22269253 doi: medRxiv preprint

The verified PBPK-DDI models of ETI were used to simulate the standard dose of ETI when co-244 administered with nirmatrelvir/ritonavir q12h for 5 days to determine the magnitude of the DDI for 245 its intended use for treatment of COVID-19. To mimic the clinical setting of nirmatrelvir/ritonavir 246 administration, we simulated steady state PK of ETI, then ritonavir q12h for 5 days while continuing 247 ETI standard dosing during and after ritonavir administrations. We calculated the Cmax and AUC 248 ratio of ETI in the presence and absence of ritonavir on day 6 of co-administration ( Table S4 ). The 249 magnitude of DDI achieves its maximum level on day 6, as ETI haven't gotten to the steady-state 250 after ritonavir administration, so drugs are still accumulating after the last dose of ritonavir ( Figure  251   2A, B, and C) . Further, the maximum CYP3A4 inhibition effect is maintained through day 6 252 ( Figure 2E) Simulation of ETI in the presence and absence of ritonavir is shown in Figure 2 . Although ritonavir 258 itself is eliminated the day after discontinuation (Figure 2D) , the CYP3A4 inhibition is time-259 dependent(24), so the inhibition is prolonged and the recovery to baseline time is reliant on the 260 turnover of the CYP3A4 itself ( Figure 2E) . Thus, baseline steady state of all ETI drugs is predicted 261 to be re-established on day 15, when the geometric mean AUC ratio (90% CI) with or without 262 ritonavir are 1.15 (1.12, 1.17), 1.13 (1.10, 1.15), and 1.17 (1.12, 1.23) for elexacaftor, tezacaftor, and 263 ivacaftor, respectively. Crucially, this indicates that dose adjustment of ETI in case of co-264 administration with nirmatrelvir/ritonavir would be required to extend beyond the 5 days of co-265 administration with ritonavir. 266 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

We next utilized the models to simulate ETI dose adjustments when these agents are co-administered 272 with ritonavir and determine how long the adjusted dosage needed to be maintained, to overcome the 273 enzyme inhibition effect mediated by ritonavir to achieve a similar level of the drug exposure of ETI 274 alone regimen. Based on the simulated effects of ritonavir, elexacaftor 200mg, tezacaftor 100mg, 275 ivacaftor 150mg in the morning (2 orange tablets) every 4 days (administered on day 1 and day 5 and 276 resumed full dose on day 9) provided similar steady-state PK profile of the conventional regimen of 277 ETI alone (Figure 3) . The trough concentrations of ETI were all above the EC50 targets, which are 278 0.99 mg/L, 0.5 mg/L, and 0.048 mg/L for elexacaftor, tezacaftor, and ivacaftor, respectively(11-13). 279

Since CYP3A4 inhibition dynamics mediated by ritonavir changes over time, we measured the mean 280

Cmax and AUC of reduced dosing of ETI regarding the first dose on day 1 and the second dose on 281 day 5 and calculated the percentage of ETI standard regimen alone ( Table 3) . The AUC(0-96h) of 282 reduced dosing regimen ranged from 83.0-142.5% of ETI alone. Resumption of the full dose of ETI 283 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 21, 2022. ; https://doi.org/10.1101/2022.01.20.22269253 doi: medRxiv preprint on day 9 is based on simulations to optimize the concentration profiles of all components of ETI, 284

where the level of elexacaftor and tezacaftor do not become lower than 80% of the standard regimen 285 before resuming the full dose, while striving to maintain levels of ivacaftor below 125% of the 286 standard regimen after resuming the full dose. At day 9, the CYP3A4 enzyme activities were 287 recovered to 60% of the steady-state values. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Day 5-9 152.8 142.5 *AUC(0-24h) for day 1-2 and day 5-6, AUC(0-96h) for day 1-5 and day 5-9. 300 301 In addition, we simulated an alternate dosing regimen, which is elexacaftor 100mg, tezacaftor 50mg, 302 ivacaftor 75mg in the morning (1 orange tablet) administered every 2 days. This regimen provided 303 concentration profiles closer to the standard regimen of ETI alone with less fluctuations of 304 peak/trough concentrations ( Figure S3 and Table S5 ). Especially for ivacaftor on day 5 which 305 showed higher Cmax (2.7 mg/L, 168.8% of standard regimen) in case of 150mg q96h, the Cmax of 306 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 21, 2022. ; https://doi.org/10.1101/2022.01.20.22269253 doi: medRxiv preprint ivacaftor was 2.1 mg/L (131.3 % of standard regimen) with the 75mg q48h. However, the dosing 307 regimen of two orange tablets every 3-4 days is consistent with recommendations for other strong 308 CYP3A inhibitors and the Cmax and AUC values between the two regimens were not demonstrably 309 different. 310

For the dosing recommendation of Tezacaftor/ivacaftor (SYMDEKO), since it is provided as a fixed 311 dose yellow tablet consisting of tezacaftor 100mg and ivacaftor 150mg, the same dosing 312 recommendation above (tezacaftor-ivacaftor 100-150mg q96h) can be applied. Therefore, with co-313 administration of nirmatrelvir/ritonavir, it should be administered as one yellow tablet every 4 days, 314 resuming the full dose on day 9. For ivacaftor 150mg tablet (KALYDECO), the same dosing 315 recommendation (one tablet q96h) can be also applied. Alternatively, the dosing interval of ivacaftor 316 could be further increased to 5 days rather than 4 days, to recapitulate similar PK profile of ivacaftor 317 standard regimen. When ivacaftor 150mg was administered on day 6 instead of day 5, the Cmax was 318 decreased to 2.5 mg/L from 2.7 mg/L and AUC(0-24h) was decreased to 48.31 mg•h/L (180.2% of 319 standard regimen) from 54.4 mg•h/L (203.0% of standard regimen) ( Table S6) . Taken together, the 320 suggested dosing schedule of CFTR modulators co-administered with nirmatrelvir/ritonavir was 321 described in Figure 4 . 322 323 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in found that the elevated concentrations of ETI were continued even after ritonavir is eliminated due to 349 the irreversible CYP3A4 inhibition effect. The suggested reduced dosing regimen that is maintained 350 until 4 days after ritonavir is discontinued provided a similar PK profile of the standard regimen of 351 ETI alone. However, dose-dependent adverse reactions of ivacaftor should be more closely 352 monitored due to its high peak concentrations on day 5. This study has important clinical 353 implications, bridging the gap between the available clinical DDI study and that of the therapeutic 354 regimen and providing proper dosing guidelines for treatment of COVID-19 with 355 nirmatrelvir/ritonavir in pwCF receiving concomitant CFTR modulator therapy. 356 A limitation of this study is that in the absence of data, population -system parameters, such as 357 plasma protein levels in pwCF patients was not incorporated into the modelling. However, changes 358 in demography reflecting a pwCF patient population was incorporated. Furthermore, a prior study 359 evaluating the hepatic clearance of drugs showing that CYP3A enzyme activity is unaffected in 360 people with CF(25) and the current weight of evidence based on comparisons of ETI PK in healthy 361 volunteers compared to patients suggests they are comparable(11-13). There is a study indicating that 362 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 21, 2022. ; https://doi.org/10.1101/2022.01.20.22269253 doi: medRxiv preprint differences in pharmacokinetics of drugs in CF can be seen which is attributed to differences in body 363 composition and plasma protein concentrations secondary to nutritional deficiencies(26). However, 364 the BMI of pwCF has increased over the years with continued improvements in CF-care, including 365 highly effective CF modulators and nutritional support(9), to the extent it is now similar to that of 366 healthy volunteers (10) . 367

A potential limitation of this work is that we did not include models of all active metabolites of 368 ETI. M1-tezacaftor is an important metabolite due to its similar potency with parent drug as well as 369 its high metabolite to parent AUC ratio (157.8%). Since M1-tezacaftor is also metabolized by 370 CYP3A with fmCYP3A of 80%(12), its formation and elimination may be altered with ritonavir co-371 administration. Using the PBPK model of M1-tezacaftor, we were able to determine that the reduced 372 dose of ETI provided mean AUC(0-96h) for M1-tezacaftor during the co-administration period with 373 ritonavir that was 80.9% of the standard regimen of ETI alone. We did not include models of active 374 metabolites of ivacaftor (M1-ivacaftor) and elexacaftor (M23-elexacaftor), since there was 375 insufficient information to build the models incorporating them. While it is currently unknown 376 whether ritonavir plus dose adjustment would alter the levels of M23-elexacaftor, the exposure of 377 this metabolite is significantly reduced when compared with the parent compound and is not 378 considered to contribute significantly to the overall efficacy(13). For M1-ivacaftor, there is evidence 379 that its plasma concentration of is decreased by 35% in the presence of rifampin, indicating that M1-380 ivacaftor may also metabolized by CYP3A(27). This perhaps suggests that the reduced dose of 381 ivacaftor may not significantly reduce M1-ivacaftor exposure when co-administered with ritonavir, 382 since ritonavir will inhibit the metabolism of both ivacaftor and M1-ivacaftor. 383

In conclusion, using a PBPK modeling approach, we demonstrated that nirmatrelvir/ritonavir can 384 be administered concomitantly with ETI in pwCF with proper dose adjustment. The outcome of this 385 study ensures the use of nirmatrelvir/ritonavir for the treatment of COVID-19 in patients with CF 386 while continuing to receive highly active CFTR modulators. In addition, this work provides tools to 387 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 21, 2022. ; https://doi.org/10.1101/2022.01.20.22269253 doi: medRxiv preprint

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor 401 combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a 402 double-blind, randomised, phase 3 trial

Pharmacokinetic and Drug-Drug Interaction Profiles of the Combination of 404

Impact of COVID-19 on people with cystic fibrosis. The Lancet 406 Respiratory medicine 8

The pathogenesis and treatment of the `Cytokine Storm' in 408 COVID-19

EMERGENCY USE 410 AUTHORIZATION FOR PAXLOVID

Predicting the Effect of CYP3A Inducers 412 on the Pharmacokinetics of Substrate Drugs Using Physiologically Based Pharmacokinetic 413 (PBPK) Modeling: An Analysis of PBPK Submissions to the US FDA

Applications of physiologically based pharmacokinetic (PBPK) modeling and 416 simulation during regulatory review

Physiologically Based Pharmacokinetic Analyses -418 Format and Content Guidance for Industry

Cystic Fibrosis Foundation Patient Registry 2020 Annual Data Report, Bethesda, Maryland 421 ©2021 Cystic Fibrosis Foundation

Increase in body mass index from normal weight to overweight in a cross-423 sectional sample of healthy research volunteers

Center for Drug Evaluation and Research. Clinical 426 Pharmacology and Biopharmaceutics review(s), Ivacaftor

Center for Drug Evaluation and Research. Clinical 430 Pharmacology and Biopharmaceutics review(s), Tezacaftor/Ivacaftor

Center for Drug Evaluation and Research. Multi-434 Discipline review, Elexacaftor/ Tezacaftor/Ivacaftor

Population-based mechanistic prediction of oral drug absorption. The AAPS 438 journal 11

Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of 441 Published Models, Applications, and Model Verification. Drug metabolism and disposition: 442 the biological fate of chemicals 43

AusPAR Attachment 1: Product Information for 444 lumacaftor ivacaftor

Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in 447 People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-448

Low free drug concentration prevents inhibition of F508del CFTR 450 functional expression by the potentiator VX-770 (ivacaftor)

CYP3A4 substrate selection and substitution 456 in the prediction of potential drug-drug interactions. The Journal of pharmacology and 457 experimental therapeutics 314

Confidence assessment of the Simcyp time-based approach and a static 459 mathematical model in predicting clinical drug-drug interactions for mechanism-based 460 CYP3A inhibitors. Drug metabolism and disposition: the biological fate of chemicals

The 463 pharmacokinetic interaction between ivacaftor and ritonavir in healthy volunteers

Characterization of ritonavir-466 mediated inactivation of cytochrome P450 3A4

Determining 468 the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors 469 using A limited sampling strategy

Pharmacokinetics in Patients with Cystic Fibrosis: A Systematic Review 471 of Data Published Between

Novel Population Pharmacokinetic Approach to Explain the Differences 473 between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding

AusPAR Attachment 2 Extract from the Clinical Evaluation Report for Lumacaftor / Ivacaftor